.svg)
Venture Medical Announces Strategic Partnership with Plasmacure to Bring Groundbreaking Cold Plasma Therapy for Chronic Wounds to the U.S. Market
Venture Medical, LLC, a leading provider of advanced wound care solutions, is proud to announce a strategic development and distribution agreement in principle with Plasmacure B.V., the Netherlands-basedMedTech innovator behind the revolutionary PLASOMA cold plasma system for chronic wound treatment.
This agreement will introduce a new technology that has already demonstrated strong results in promoting wound healing to the UnitedStates. Under the terms of the agreement, Venture Medical will lead the FDA approval process. Once regulatory approval has been secured, Venture Medical will serve as Plasmacure’s exclusiveU.S. commercialization partner, supporting market entry, clinician education, and nationwide distribution of the CE-marked PLASOMA cold plasma device.
“The Plasoma cold plasma system represents the kind of patient-first innovation our industry needs,” said John Schroeder, VentureMedical CEO. “At Venture Medical we are willing to invest in long-term solutions for patients who currently have few good options for treating difficult-to-heal wounds.”
Plasmacure’s PLASOMA system delivers cold plasma derived from room air directly to chronic wounds through a unique flexible pad, safely initiating multiple mechanisms of action which are well known to speed healing. As rates of diabetic foot ulcers and other non-healing wounds continue to rise in the U.S., this system will offer a timely and effective response.
More details about the commercial path for PLASOMA and educational initiatives around the technology are forthcoming.
To learn more about PLASOMA or to learn more about the ability to partner with Venture Medical, visit www.venturemedical1.com or www.plasmacure.nl.
Popular Posts
Categories
Avoiding wound care for free, a.k.a. surviving a “bad faith” audit.
Audits are meant to protect against fraud, but in wound care many providers are now facing aggressive “bad faith” audits driven by financial incentives and bias. This blog explores what’s behind the rise in these audits, their impact on patients and practitioners, and the steps providers can take to prepare, push back, and protect their practices.
The price patients will pay for the PFS
After a recent survey we conducted, it is clear most clinicians agreed skin substitutes are highly effective and essential, warning that the proposed rates would reduce patient access, hinder innovation, and threaten the viability of many practices. Read the blog to learn more about our findings.
The Case For Mobile Wound Care: An Essential Component Of Chronic Wound Management
Mobile wound care is a critical yet often misunderstood part of chronic wound management, providing advanced treatment to patients who can't easily access traditional care. Far from being a fringe service, it’s a large and growing field—with nearly 30,000 clinicians billing for mobile wound services in 2023 alone—and plays a key role in addressing the rising burden of chronic wounds, especially in nursing homes. As wound severity increases, staffing shortages persist, and the population ages, mobile providers are filling care gaps through high-volume, high-quality services and innovative tools like AI-assisted telehealth and near-infrared spectroscopy. To ensure better outcomes and lower healthcare costs, policymakers and payers must recognize mobile wound care as an essential, professional solution—not a peripheral one.
Venture Position on CMS and MAC Skin Substitute Proposals
Venture Medical, LCC is sharing our position on the CY2026 Medicare Physician Fee Schedule and our future recommendations.
